1. 2013 performance Overview:
Income during the period was 915 million yuan, up 6.8% from the same period last year; gross profit was 403 million yuan, up 24.3% from the same period last year; gross profit margin was 44.1%, up from 37.9% in 2012; net profit rate was 16.7%, 3.3% higher than 12-year net interest rate of 13.4%; net profit of equity shareholders was 153 million yuan, up 33.7% from the same period last year. Basic earnings per share increased to 0.1910 yuan from 0.1432 yuan in 2012, with a dividend of 0.068 Hong Kong dollars per share, up from 0.055 Hong Kong dollars in 2012.
2. Main financial indicators:
The company's current ratio was 1.71, compared with 1.64 in 2012; the turnover of accounts receivable was 154, down 24 days from 178 days in 2012; the turnover of inventory was 119 days, compared with 121 days in 2012; the asset-liability ratio fell to 36.6% from 37.4% in 2012; cash inflows from operating activities were 231 million yuan, an increase of nearly 20 million compared with 203 million yuan in 12 years. Cash and cash equivalents decreased from 59,491 thousand yuan in 12 years to 53066 thousand yuan. At present, the company is full of funds, and the available cash reaches 240 million yuan.
3. Capital expenditure:
In 2014, capital expenditure is expected to be 90 million yuan, of which 30 million yuan will be used for the final payment for the construction of the Hedong plant and 60 million yuan for the transformation of the new GMP.
4. Business sales in 2013:
The company increased the production and sales of specialist drug products, consolidated and expanded the market share of system specialty drugs. The production and sales of "an" series increased by 43.6% and 26.7% compared with the same period in 2012. The production and sales of "Lei Yi de" increased by 46.6% and 49.9% compared with the same period in 2012.
Antibiotic products are affected by the national anti-resistance policy. In the second half of 13 years, the company began to transform its GMP workshop and stopped the sale of raw materials. The sales volume of cephalosporin injection decreased by 23.1% compared with the same period in 2012 (but oral cephalosporin recorded a 40% increase).
Sales of intermediates and APIs decreased by 0.14% compared with the same period in 2012.